Introducing Fycompa (Perampanel): Advanced Seizure Control for Epilepsy

Fycompa, containing the active substance perampanel, is a groundbreaking medication designed to provide effective adjunctive treatment for various types of seizures in epilepsy patients. Manufactured by Eisai Europe Ltd, Fycompa is approved by leading regulatory authorities, including the European Medical Agency (EMA), the Food and Drug Administration (FDA), Health Canada, and the Therapeutic Goods Administration (TGA).

Disease Indications:

Epilepsy: Fycompa is utilized in the management of epilepsy, offering comprehensive seizure control for both partial-onset seizures and primary generalized tonic-clonic seizures.

Usage:

Oral: Fycompa is administered orally, ensuring ease of use and patient compliance.

Therapeutic Benefits:

1. Partial-Onset Seizures: Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in adults and adolescents aged 12 years and older. Its efficacy in controlling these seizures helps improve patients’ quality of life and reduces the frequency of disruptive episodes.
2. Primary Generalized Tonic-Clonic Seizures: Fycompa is also effective for the adjunctive treatment of primary generalized tonic-clonic seizures in adults and adolescents aged 12 years and older with idiopathic generalized epilepsy. By managing these severe seizures, Fycompa provides crucial support in the comprehensive management of epilepsy.

Manufacturer:

Eisai Europe Ltd: A trusted name in pharmaceutical innovation, Eisai Europe Ltd is dedicated to advancing epilepsy treatment through rigorous research and development.

Regulatory Approvals:

• European Medical Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Therapeutic Goods Administration (TGA)

These approvals underline the high standards of quality, safety, and efficacy that Fycompa meets, making it a reliable choice for healthcare professionals and patients alike.

Empowering Epilepsy Management:

Fycompa offers a targeted approach to epilepsy treatment, helping patients manage their condition more effectively. With its proven track record in reducing seizure frequency and improving overall control, Fycompa is a valuable addition to epilepsy therapy regimens.

Trust Fycompa for advanced seizure control and improved quality of life. Backed by science, approved by global health authorities, and trusted by healthcare professionals, Fycompa is your partner in managing epilepsy with confidence.